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Phosphoinositide 3-Kinase (PI3K) is a central enzyme in a
signaling pathway that mediates cellular responses to insu-
lin and other growth factors. This enzyme phosphorylates
the 3 position of phosphatidylinositol-4,5-bisphosphate to
produce phosphatidyl-inositol-3,4,5-trisphosphate (PIP3)
at the plasma membrane. A number of signaling proteins,
including the Ser/Thr protein kinases, AKT and PDK1,
contain pleckstrin homology domains that bind specifically
to PIP3. Thus, the generation of PIP3 at the plasma mem-
brane in response to activation of PI3K by growth factors
results in the initiation of downstream Ser/Thr phosphory-
lation cascades that control a variety of cellular responses.
The signaling pathway downstream of PI3K is highly con-
served from worms and flies to humans and genetic analy-
sis of the pathway has revealed a conserved role in
regulating glucose metabolism and cell growth. Based on
deletion of genes encoding the catalytic or regulatory sub-
units of PI3K in the mouse, PI3K mediates insulin depen-
dent regulation of glucose metabolism, and defects in
activation of this pathway result in insulin resistance. In
contrast, mutational events that lead to hyperactivation of
the PI3K pathway result in cancers. Activating mutations
in PIK3CA, encoding the p110alpha catalytic subunit of
PI3K or inactivating mutations in PTEN, a phosphoinosi-
tide 3-phosphatases that reverses the effects of PI3K, are
among the most common events in solid tumors. PI3K
driven tumors are FDG-PET positive and turning off PI
3-Kinase with PI3K inhibitors that are in human clinical
trials results in an acute decline in FDG-PET signal that
precedes tumor shrinkage. Importantly, there is increasing
evidence that some tumors express high levels of insulin
receptor and activate PI3K due to elevated serum insulin
in patients with insulin resistance. These results suggest
that elevations in serum insulin may partially explain the
link between obesity, diabetes and cancers. The role of
PI3K inhibitors for treating cancers in mouse models and
in human trials will be discussed.
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